{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(7)"],"submitter":["Abadir E"],"pubmed_abstract":["Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost of significant treatment-related mortality. Despite the reduction in relapse overall, it remains common, especially in high-risk groups. The outcomes for patients who relapse after transplant remains very poor. A large proportion of the morbidity that prevents most patients from accessing allo-HSCT is due to toxic nonspecific conditioning agents that are required to remove recipient hematopoietic stem and progenitor cells (HSPCs), allowing for successful donor engraftment. CD300f is expressed evenly across HSPC subtypes. CD300f has transcription and protein expression equivalent to CD33 on AML. We have developed an anti-CD300f antibo"],"journal":["Blood advances"],"pagination":["1206-1216"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7160263"],"repository":["biostudies-literature"],"pubmed_title":["Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia."],"pmcid":["PMC7160263"],"pubmed_authors":["Kabani K","Bryant CE","Sutherland S","Mekkawy AH","Larsen SR","Ramesh M","Romano A","Gasiorowski RE","Lo TH","Abadir E","Pietersz GA","Silveira PA","Ho PJ","Clark GJ"],"additional_accession":[]},"is_claimable":false,"name":"Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.","description":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost of significant treatment-related mortality. Despite the reduction in relapse overall, it remains common, especially in high-risk groups. The outcomes for patients who relapse after transplant remains very poor. A large proportion of the morbidity that prevents most patients from accessing allo-HSCT is due to toxic nonspecific conditioning agents that are required to remove recipient hematopoietic stem and progenitor cells (HSPCs), allowing for successful donor engraftment. CD300f is expressed evenly across HSPC subtypes. CD300f has transcription and protein expression equivalent to CD33 on AML. We have developed an anti-CD300f antibo","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2026-05-01T23:56:53.169Z","creation":"2025-04-04T07:20:18.013Z"},"accession":"S-EPMC7160263","cross_references":{"pubmed":["32215656"],"doi":["10.1182/bloodadvances.2019001289"]}}